JP6076913B2 - 癌からの転移を阻害する方法 - Google Patents

癌からの転移を阻害する方法 Download PDF

Info

Publication number
JP6076913B2
JP6076913B2 JP2013543275A JP2013543275A JP6076913B2 JP 6076913 B2 JP6076913 B2 JP 6076913B2 JP 2013543275 A JP2013543275 A JP 2013543275A JP 2013543275 A JP2013543275 A JP 2013543275A JP 6076913 B2 JP6076913 B2 JP 6076913B2
Authority
JP
Japan
Prior art keywords
compound
substituted
alkyl
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013543275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508720A5 (enExample
JP2014508720A (ja
Inventor
アレッサンドロ ファタチス
アレッサンドロ ファタチス
ジョセフ エム． サルヴィーノ
ジョセフ エム． サルヴィーノ
オリンピア メウッチ
オリンピア メウッチ
ホイットニー エル． ジェーミソン
ホイットニー エル． ジェーミソン
Original Assignee
ドレクセル ユニバーシティ
ドレクセル ユニバーシティ
アライアンス ディスカバリー インコーポレイテッド
アライアンス ディスカバリー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドレクセル ユニバーシティ, ドレクセル ユニバーシティ, アライアンス ディスカバリー インコーポレイテッド, アライアンス ディスカバリー インコーポレイテッド filed Critical ドレクセル ユニバーシティ
Publication of JP2014508720A publication Critical patent/JP2014508720A/ja
Publication of JP2014508720A5 publication Critical patent/JP2014508720A5/ja
Application granted granted Critical
Publication of JP6076913B2 publication Critical patent/JP6076913B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013543275A 2010-12-07 2011-12-06 癌からの転移を阻害する方法 Expired - Fee Related JP6076913B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42064010P 2010-12-07 2010-12-07
US61/420,640 2010-12-07
PCT/US2011/063533 WO2012078633A2 (en) 2010-12-07 2011-12-06 Methods of inhibiting metastasis from cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017002396A Division JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Publications (3)

Publication Number Publication Date
JP2014508720A JP2014508720A (ja) 2014-04-10
JP2014508720A5 JP2014508720A5 (enExample) 2015-01-29
JP6076913B2 true JP6076913B2 (ja) 2017-02-08

Family

ID=46162450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013543275A Expired - Fee Related JP6076913B2 (ja) 2010-12-07 2011-12-06 癌からの転移を阻害する方法
JP2017002396A Pending JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017002396A Pending JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Country Status (4)

Country Link
US (4) US8435993B2 (enExample)
EP (1) EP2648754A4 (enExample)
JP (2) JP6076913B2 (enExample)
WO (1) WO2012078633A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017122085A (ja) * 2010-12-07 2017-07-13 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
US12630555B2 (en) 2024-01-02 2026-05-19 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883989B2 (en) * 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
CN104245735B (zh) * 2012-02-27 2018-02-23 勃林格殷格翰国际有限公司 Cx3cr1结合多肽
JP2016534114A (ja) * 2013-08-21 2016-11-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘ３ｃｒ１標的化イメージング剤並びに疾病の診断及び処置におけるその使用
WO2016024096A1 (en) * 2014-08-11 2016-02-18 Redx Pharma Plc Antibacterial compounds
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
WO2019014122A1 (en) * 2017-07-08 2019-01-17 The Brigham And Women's Hospital, Inc. METHODS FOR ENHANCING ANTIANGIOGENIC THERAPY AND IMMUNOTHERAPY
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP4003972A4 (en) * 2019-07-23 2023-07-12 Board of Regents, The University of Texas System BICYCLIC RECEPTOR AGONISTS
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法
CN116075512A (zh) 2020-06-11 2023-05-05 Chdi基金会股份有限公司 用于对亨廷顿蛋白成像的杂环化合物和显像剂
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939159A (en) * 1974-05-29 1976-02-17 American Hoechst Corporation Spiro(pyrrolo (1,2-A)quinoxalines)
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
DE4228095A1 (de) * 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
AU2000273378A1 (en) 2000-02-18 2001-08-27 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US20020010125A1 (en) 2000-03-16 2002-01-24 Carson Dennis A. Assay for agents that induce chemokinesis
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003052082A2 (en) 2001-12-18 2003-06-26 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
WO2005033115A1 (en) * 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
US20060115834A1 (en) * 2004-10-19 2006-06-01 University Of Iowa Research Foundation Methods of identifying metastatic potential in cancer
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
RU2437889C2 (ru) 2006-09-29 2011-12-27 Астразенека Аб НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
KR20140139125A (ko) * 2007-08-31 2014-12-04 퍼듀 퍼머 엘피 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
EP2262778B8 (en) * 2008-03-07 2020-01-01 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
AR071036A1 (es) 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
JP5351254B2 (ja) * 2008-05-23 2013-11-27 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
MX2011002636A (es) * 2008-09-11 2011-04-05 Chemocentryx Inc 4-amino-3-(imidazoil)-pirazolo[3,4-d]pirimidinas.
JP2011127042A (ja) 2009-12-18 2011-06-30 Fujifilm Corp アゾ顔料、アゾ顔料の製造方法、アゾ顔料を含む分散物、及び着色組成物
US8785490B2 (en) * 2010-04-09 2014-07-22 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017122085A (ja) * 2010-12-07 2017-07-13 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
US10414771B2 (en) 2010-12-07 2019-09-17 Drexel University Compounds useful for inhibiting metastasis from cancer and methods using same
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
US12152036B2 (en) 2017-05-02 2024-11-26 Drexel University Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CX3CR1 antagonists
US12630555B2 (en) 2024-01-02 2026-05-19 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists

Also Published As

Publication number Publication date
WO2012078633A3 (en) 2013-12-27
WO2012078633A8 (en) 2012-09-13
EP2648754A2 (en) 2013-10-16
EP2648754A4 (en) 2016-02-24
WO2012078633A2 (en) 2012-06-14
US20120141471A1 (en) 2012-06-07
US9856260B2 (en) 2018-01-02
JP2017122085A (ja) 2017-07-13
US20180099972A1 (en) 2018-04-12
US10414771B2 (en) 2019-09-17
US9375474B2 (en) 2016-06-28
US20160264587A1 (en) 2016-09-15
US20130156761A1 (en) 2013-06-20
JP2014508720A (ja) 2014-04-10
US8435993B2 (en) 2013-05-07

Similar Documents

Publication Publication Date Title
US10414771B2 (en) Compounds useful for inhibiting metastasis from cancer and methods using same
ES2537518T3 (es) Moléculas que inhiben una ruta metabólica que implica la proteína tirosina quinasa Syk y procedimiento de identificación de dichas moléculas
JP2024045336A (ja) インドールアミン２，３－ジオキシゲナーゼを阻害するための医薬組成物と方法、及びその適応
US9421208B2 (en) Methods for the treatment of solid tumors
CA2908954C (en) Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
CN105209449B (zh) 犬尿氨酸途径的抑制剂
KR20070108270A (ko) 술폰아미드 화합물의 신규 병용
BR112015026297B1 (pt) Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
AU2013262914A1 (en) Pre-selection of subjects for therapeutic treatment with an Hsp90 inhibitor based on hypoxic status
EA030808B1 (ru) ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
JP2018537519A (ja) 癌の治療のための合理的併用療法
EP3906234A1 (en) Quinoline compounds as inhibitors of tam and met kinases
JP7759032B2 (ja) 脳血管攣縮抑制剤
KR101941045B1 (ko) 암의 예방 또는 치료용 약학적 조성물
Sanders Sigma1 as a Ligand-Operated Scaffolding Protein that Regulates the Activity of Oncogenic Driver and Immunomodulatory Proteins in Cancer Cells
HK1240076B (zh) 联用药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150323

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20150522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170111

R150 Certificate of patent or registration of utility model

Ref document number: 6076913

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees